Vaginal Candidiasis: Causes, Symptoms, Diagnosis, and Treatment

What Vaginal Candidiasis Is

Vaginal candidiasis occurs when yeast from the Candida genus multiplies excessively in the vaginal environment. The most frequent species involved is Candida albicans, although other species such as C. glabrata, C. tropicalis, C. parapsilosis, and C. kefyr may also cause infection.

These microorganisms normally exist in the vaginal microbiome without causing disease. Under certain conditions, however, the balance between yeast and protective bacteria changes. When yeast growth becomes dominant, the vaginal lining becomes irritated and inflamed.

Because Candida organisms are usually already present in the body, the infection typically develops from internal imbalance rather than from external transmission.

Factors That Promote Infection

Several biological and lifestyle factors can favor fungal overgrowth.

Common contributing factors include:

• elevated blood glucose levels, particularly in diabetes

• hormonal changes during the menstrual cycle or pregnancy

• hormonal contraceptives or hormone therapy

• antibiotic use that disrupts protective vaginal bacteria

• weakened immune defenses due to illness, stress, or medication

• frequent vaginal douching

• use of scented hygiene products

• tight or synthetic underwear that traps moisture

• prolonged use of internal menstrual products

• nutritional factors that affect immune function

Although vaginal candidiasis is not generally classified as a sexually transmitted infection, yeast may be transferred during sexual contact, particularly if one partner has symptoms.

Symptoms

Symptoms vary in intensity and may develop gradually or appear suddenly.

Typical signs include:

• intense itching of the vulva and vagina

• redness and swelling of the external genital area

• burning during urination

• discomfort or pain during sexual intercourse

• vaginal soreness or pressure

• thick white discharge with a clumped or “curd-like” appearance

Some women experience mild irritation, while others develop symptoms severe enough to interfere with daily activities. In recurrent infections, inflammation may extend beyond the vaginal lining and contribute to pelvic discomfort or dyspareunia.

Occasionally, the infection produces no noticeable symptoms and is discovered during routine gynecological examination.

Diagnosis

Accurate diagnosis requires medical evaluation, especially when symptoms occur for the first time or recur frequently.

A gynecological examination may be followed by laboratory testing of vaginal secretions. Microscopic analysis can reveal yeast cells and pseudohyphae, which indicate fungal growth.

In recurrent or persistent infections, vaginal culture may be performed to identify the specific Candida species involved. Laboratory analysis may also determine antifungal susceptibility, helping clinicians select the most effective treatment.

Treatment

Most cases respond well to antifungal therapy when treatment is appropriate for the specific infection.

Therapeutic options include:

• topical antifungal medications applied locally

• oral antifungal medications in selected cases

The choice of therapy depends on symptom severity, patient preferences, pregnancy status, and medical history. Local treatment is often recommended during pregnancy, while oral medications may be used in non-pregnant individuals when clinically appropriate.

Completing the full course of treatment is important. Stopping therapy prematurely increases the risk of recurrence.

In recurrent or treatment-resistant infections, additional approaches may be required. These may include longer treatment regimens, therapies targeting fungal biofilms, or treatment of sexual partners in certain situations.

Follow-up evaluation may be recommended to confirm resolution and help restore normal vaginal microbial balance.

How Common Vaginal Candidiasis Is

Approximately three quarters of women experience at least one episode during their lifetime. A smaller proportion, estimated at five to eight percent, develop recurrent candidiasis, typically defined as four or more episodes per year.

The infection occurs most frequently during reproductive years, when hormonal fluctuations influence the vaginal environment. After bacterial vaginosis, candidiasis is among the most common vaginal infections.

When Medical Evaluation Is Recommended

Medical consultation is advisable when:

• symptoms occur for the first time

• symptoms are severe or persistent

• infections recur frequently

• pain during intercourse or pelvic pain develops

• fertility concerns arise

• symptoms fail to improve with treatment

Prompt evaluation helps ensure correct diagnosis and reduces the risk of complications.

Prevention

Preventive measures focus on maintaining a balanced vaginal microbiome and minimizing conditions that promote yeast overgrowth.

Helpful practices include:

• wearing breathable cotton underwear

• avoiding unnecessary vaginal douching

• using fragrance-free intimate hygiene products

• changing wet clothing promptly

• maintaining balanced blood glucose levels

• using antibiotics only when medically necessary

• supporting immune health through balanced nutrition

These strategies can reduce recurrence risk, particularly in women with a history of repeated infections.

Selected Scientific References

Sobel JD. Vulvovaginal candidosis. The Lancet. 2007;369(9577):1961–1971.

Pappas PG et al. Clinical practice guideline for the management of candidiasis: 2016 update by the Infectious Diseases Society of America. Clinical Infectious Diseases. 2016;62(4):e1–e50.

Fidel PL Jr., Sobel JD. Immunopathogenesis of recurrent vulvovaginal candidiasis. Clinical Microbiology Reviews. 1996;9(3):335–348.

Ilkit M, Guzel AB. The epidemiology, pathogenesis, and diagnosis of vulvovaginal candidosis. Critical Reviews in Microbiology. 2011;37(3):250–261.

Denning DW et al. Global burden of recurrent vulvovaginal candidiasis. The Lancet Infectious Diseases. 2018;18(11):e339–e347.

Donders GGG et al. Management of recurrent vulvovaginal candidosis as a chronic illness. The Lancet Infectious Diseases. 2022;22(8):e273–e285.

Cassone A. Vulvovaginal Candida albicans infections: pathogenesis, immunity and vaccine prospects. BJOG. 2015;122(6):785–794.

Workowski KA et al. Sexually transmitted infections treatment guidelines. CDC MMWR Recommendations and Reports. 2021.